Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling
about
Somatic mutations in disorders with disrupted brain connectivityIn Vivo Delivery Systems for Therapeutic Genome EditingBrain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the futureApplications of CRISPR-Cas systems in neuroscienceThe CRISPR revolution and its impact on cancer researchGenetically engineered mouse models in oncology research and cancer medicineSomatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia.CRISPR/Cas9: Transcending the Reality of Genome Editing.Annexin A2 Modulates ROS and Impacts Inflammatory Response via IL-17 Signaling in Polymicrobial Sepsis Mice.piggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in miceTracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling.CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirsRapid tumor induction in zebrafish by TALEN-mediated somatic inactivation of the retinoblastoma1 tumor suppressor rb1Tissue-specific tumorigenesis: context matters.PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotypeOptic pathway gliomas in neurofibromatosis-1: controversies and recommendations.Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme.Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery.Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS.CRISPR/Cas9-induced disruption of gene expression in mouse embryonic brain and single neural stem cells in vivo.Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice.CNS Tumors in Neurofibromatosis.Therapeutic genome engineering via CRISPR-Cas systems.The application of somatic CRISPR-Cas9 to conditional genome editing in Caenorhabditis elegans.The application of CRISPR technology to high content screening in primary neurons.TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevant Xenopus tropicalis tumor models.The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal modelsThe present and future of genome editing in cancer research.Applications of the CRISPR/Cas9 system in murine cancer modeling.Somatic Engineering of Oncogenic Chromosomal Rearrangements: A PerspectiveCRISPR: a versatile tool for both forward and reverse genetics research.In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS.Development of zebrafish medulloblastoma-like PNET model by TALEN-mediated somatic gene inactivation.Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells."CRISPR" validation of recessive brain cancer genes in vivo.CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas.
P2860
Q26747309-64F0AEA1-A21A-439A-A50A-F1E49AFA44D5Q26748886-4A1F67FA-D103-4D97-9CBE-1EDB9DD18D54Q26753206-AC205776-2C6B-4D59-B437-8D3E234714D8Q26776515-75408A71-7F5E-44A3-9FC0-F310C6BAE53EQ26824997-6C347470-A7AE-498E-A34E-CA7BEE03F62CQ28079323-7513B984-6B34-4AFA-BB0A-ADB45F7041F5Q30274618-99FD535A-0C7B-4762-8272-44323D8C4228Q33632925-B8090C61-1C1F-41BA-AE82-BF320398E29EQ36070617-33A8F159-E9F4-4F27-80AD-6BFFB1D26EECQ36243531-F0889150-EDD3-4D33-A23C-39A978429E3CQ36245097-EAEC8787-E862-4E1B-A1EA-0FBD1C75E3E4Q36250079-F8412301-0668-4A14-B558-A09BE2B8D229Q36273681-1F51CF8D-7976-46EA-B33D-B8D0C8B620A2Q36296335-DDD5E9E5-B580-44A7-9325-3102B93A21C2Q36392356-B2825575-217F-4050-854B-EF1949F6081EQ36771546-1B3C2455-C1D5-4100-A2A8-3461F6CBAB98Q37051766-2C3CFF52-D9E5-4EB5-BD75-269E7D89BF03Q37330941-38181D79-6944-4BB2-A7C8-6FBFCCB8A7D2Q37719291-D64281C6-ED14-4645-B7B2-76D7DECABE0CQ38682882-B1041FA9-E33E-431D-A5B6-6F13716EAD13Q38687781-F3E29595-5EBD-412A-937C-20641A683AB8Q38699787-F87500DA-D932-4C81-BE1E-E751842677D6Q38707232-285073C1-65B5-4971-B968-0488F8D3FB3AQ38713914-D97017F2-659D-4D90-B8EB-634BACE69407Q38757432-A8416CE9-1EFD-4335-A56C-9EEF40C954B9Q38757952-7533C48C-0B6D-4E95-B1C1-B6BF893755E8Q38767473-6F8E8877-AEC3-4E03-A440-79DF7BD43401Q38769494-BE46B406-E1B2-452C-A0C5-6C45079CB3D7Q38836751-E0DF3078-6E4A-4BDC-9396-F42D22041DF3Q38840267-7715B195-1A2F-4AD9-9043-05C60DF9748BQ38858314-44560AB9-A607-4465-8A01-99E0CFC2FD85Q38926441-F1FBB3AC-9149-4984-9887-D53A47F16FF2Q39627059-8131A131-6CBD-45E0-90D3-3EF45821BDAEQ40263108-F398CDF2-8785-4DA5-B56D-1BE993BF0BCCQ40829178-81403E7C-DD61-4F3B-B088-C53EC7971FC9Q41548915-ACC8AE9E-93C5-4FD9-8CBE-CBD28AB2B9B1Q41701616-D61060A8-D741-4D9A-91D7-353B1CB38501Q42605129-563CBBC4-5108-4D79-9F72-0EC0573D42FEQ47141255-8C05F69C-0453-439D-B92B-432BAACF15DFQ47436402-ABA90AB2-60A6-482D-84CF-71C374CEC17B
P2860
Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling
@ast
Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling
@en
type
label
Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling
@ast
Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling
@en
prefLabel
Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling
@ast
Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling
@en
P2093
P2860
P50
P356
P1476
Somatic CRISPR/Cas9-mediated t ...... rsatile brain tumour modelling
@en
P2093
Andrey Korshunov
Barbara Tschida
Branden Moriarity
Christiane B Knobbe-Thomsen
Daisuke Kawauchi
David Largaespada
David T W Jones
Jan Gronych
Jelena Belic
Kathrin Schramm
P2860
P2888
P356
10.1038/NCOMMS8391
P407
P577
2015-06-11T00:00:00Z